Movement Alert｜TRANSTHERA-B Rises 21.51% in Regular Trading, Core Drug Tinengotinib Receives NMPA Conditional Approval

Market Focus08-07

On August 7, TRANSTHERA-B rose 21.51% in regular trading, trading at HKD 13.98/share, with turnover of HKD 62.53 million.

On the news front, the company announced on August 6 that its independently developed Class 1 new drug Tinengotinib received conditional approval from China's National Medical Products Administration (NMPA) for the treatment of adult patients with advanced, metastatic, or unresectable cholangiocarcinoma harboring FGFR2 fusions or rearrangements who have previously received systemic therapy and FGFR inhibitor treatment. The drug had previously been granted priority review and breakthrough therapy designation by NMPA. The approval was based on a multicenter, open-label, single-arm Phase II pivotal clinical trial conducted in China.

Additionally, the global registrational Phase III clinical trial of Tinengotinib for advanced cholangiocarcinoma completed patient enrollment in July, further clarifying its commercialization outlook. The company has also conducted intensive share buybacks since July, accumulating over HKD 7 million in repurchases, signaling management confidence in company value.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1134394496?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-07 09:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1134394496","market":"hk","top_or_hot":-1,"title":"Movement Alert｜TRANSTHERA-B Rises 21.51% in Regular Trading, Core Drug Tinengotinib Receives NMPA Conditional Approval","media":"Market Focus","content":"<p><p>On August 7, TRANSTHERA-B rose 21.51% in regular trading, trading at HKD 13.98/share, with turnover of HKD 62.53 million.</p><p>On the news front, the company announced on August 6 that its independently developed Class 1 new drug Tinengotinib received conditional approval from China's National Medical Products Administration (NMPA) for the treatment of adult patients with advanced, metastatic, or unresectable cholangiocarcinoma harboring FGFR2 fusions or rearrangements who have previously received systemic therapy and FGFR inhibitor treatment. The drug had previously been granted priority review and breakthrough therapy designation by NMPA. The approval was based on a multicenter, open-label, single-arm Phase II pivotal clinical trial conducted in China.</p><p>Additionally, the global registrational Phase III clinical trial of Tinengotinib for advanced cholangiocarcinoma completed patient enrollment in July, further clarifying its commercialization outlook. The company has also conducted intensive share buybacks since July, accumulating over HKD 7 million in repurchases, signaling management confidence in company value.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜TRANSTHERA-B Rises 21.51% in Regular Trading, Core Drug Tinengotinib Receives NMPA Conditional Approval</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜TRANSTHERA-B Rises 21.51% in Regular Trading, Core Drug Tinengotinib Receives NMPA Conditional Approval\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-08-07 09:31</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On August 7, TRANSTHERA-B rose 21.51% in regular trading, trading at HKD 13.98/share, with turnover of HKD 62.53 million.</p><p>On the news front, the company announced on August 6 that its independently developed Class 1 new drug Tinengotinib received conditional approval from China's National Medical Products Administration (NMPA) for the treatment of adult patients with advanced, metastatic, or unresectable cholangiocarcinoma harboring FGFR2 fusions or rearrangements who have previously received systemic therapy and FGFR inhibitor treatment. The drug had previously been granted priority review and breakthrough therapy designation by NMPA. The approval was based on a multicenter, open-label, single-arm Phase II pivotal clinical trial conducted in China.</p><p>Additionally, the global registrational Phase III clinical trial of Tinengotinib for advanced cholangiocarcinoma completed patient enrollment in July, further clarifying its commercialization outlook. The company has also conducted intensive share buybacks since July, accumulating over HKD 7 million in repurchases, signaling management confidence in company value.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02617","symbol_name":"药捷安康-B","start_time":0,"source_url":"","article_id":"1134394496","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1134394496","pubTimestamp":1786066277,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On August 7, TRANSTHERA-B rose 21.51% in regular trading, trading at HKD 13.98/share, with turnover of HKD 62.53 million.On the news front, the company announced on August 6 that its independently...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02617":"药捷安康-B"},"translate_title":"异动预警|TRANSTHERA-B常规交易大涨21.51%，核心药物替奈戈替尼获NMPA有条件批准","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02617":1},"content_text":"On August 7, TRANSTHERA-B rose 21.51% in regular trading, trading at HKD 13.98/share, with turnover of HKD 62.53 million.On the news front, the company announced on August 6 that its independently developed Class 1 new drug Tinengotinib received conditional approval from China's National Medical Products Administration (NMPA) for the treatment of adult patients with advanced, metastatic, or unresectable cholangiocarcinoma harboring FGFR2 fusions or rearrangements who have previously received systemic therapy and FGFR inhibitor treatment. The drug had previously been granted priority review and breakthrough therapy designation by NMPA. The approval was based on a multicenter, open-label, single-arm Phase II pivotal clinical trial conducted in China.Additionally, the global registrational Phase III clinical trial of Tinengotinib for advanced cholangiocarcinoma completed patient enrollment in July, further clarifying its commercialization outlook. The company has also conducted intensive share buybacks since July, accumulating over HKD 7 million in repurchases, signaling management confidence in company value.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1134394496","isCrawlerRequest":true}